Hongyue Dai

Hongyue Dai serves as the VP of Translational Bioinformatics, bringing over two decades of expertise in oncology, immuno-oncology, and neural-immune interactions. He is recognized for his proficiency in building and leading bioinformatics teams and capabilities to support drug discovery and development pipelines. Previously, Dai held senior positions at Cygnal Therapeutics, including SVP and VP of Bioinformatics and Digital Biology, where he built a robust Bioinformatics team to support Omics and image analysis pipelines. He also identified predictive biomarkers and patient populations for internal programs at Cygnal Therapeutics. At M2Gen, Dai served as Chief Scientific and Bioinformatics Officer, where he developed and executed the molecular strategy for the ORIEN Avatar program, sequencing 11,000 cancer patients by 2019. His career also includes a role as Executive Director, Informatics Analyst at Merck, where he led a global team focused on applying genomic and genetic technologies to impact Merck’s pipeline. Dai’s academic background is distinguished, having contributed significantly to the discovery of the highest energy cosmic ray ever observed, the Oh-My-God particle. He holds a B.S. in Nuclear Physics from Peking University and a Ph.D. from the Institute of High Energy Physics, Chinese Academy of Science in Beijing, China.